New Two-Drug sequence aims to extend life in pancreatic cancer

NCT ID NCT05065801

Recruiting now Disease control Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving two different chemotherapy combinations one after the other works better than the standard single combination for people with metastatic pancreatic cancer. About 162 adults aged 18 to 75 with confirmed disease will be randomly assigned to either the sequential treatment or the standard alone. The main goal is to see which approach delays cancer growth longer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PANCREATIC CANCER

Contacts and locations

Locations

CH de Perpignan
RECRUITING

Perpignan, Pyrénées-Orientales, 66046, France
CHU Grenoble
NOT_YET_RECRUITING

Grenoble, Auvergne-Rhône-Alpes, 38000, France
CHU St Eloi
RECRUITING

Montpellier, Herault, 34295, France
CHU St Etienne
ACTIVE_NOT_RECRUITING

Saint-Etienne, Auvergne-Rhône-Alpes, 42000, France
Centre Catalan d'Oncologie
NOT_YET_RECRUITING

Perpignan, Pyrénées-Orientales, 66000, France
Centre Georges-François Leclerc
RECRUITING

Dijon, 21079, France
Institut GODINOT
RECRUITING

Reims, Grand Est, 51100, France
Institut régional du Cancer de Montpellier
RECRUITING

Montpellier, Hérault, 34298, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.